Belzutifan is an oral tablet approved for the treatment of patients with renal cell carcinoma (RCC), central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors associated with Schilling (VHL) syndrome that do not require immediate surgery. Welireg is the first approved systemic therapy for the treatment of VHL syndrome. So, how to take Belzutifan(Welireg) dosage?

What is the dosage of Belzutifan and how to take it?

VHL syndrome

VHL syndrome is a rare and serious genetic disorder that puts patients at risk of developing benign vascular tumors as well as a variety of cancers, including RCC. RCC occurs in up to 70% of patients with VHL syndrome, which is the leading cause of death in patients with VHL syndrome. Welireg is a novel, potent, selective, oral hypoxia-inducible factor-2α (HIF-2α) inhibitor that targets HIF-2α, blocks cell growth, proliferation, and prevents abnormal vascularization.

Belzutifan dosage

The recommended dose of Belzutifan is 120 mg orally once daily until disease progression or unacceptable toxicity.

How to take Belzutifan?

Belzutifan should be taken at the same time every day, with or without food. Patients are advised to swallow the tablets whole. Do not chew, crush or break Belzutifan before swallowing.

How to deal with missed doses

If you miss a dose of Belzutifan, you can take it as soon as possible on the same day. The usual daily dosing regimen of Belzutifan was resumed the next day. Do not take additional tablets to make up for missed doses. Do not retake the medication if vomiting occurs at any time after taking Belzutifan. Take the next dose the next day.

Dose adjustment for adverse effects

First dose reduction: Belzutifan orally once daily

Second dose reduction: Belzutifan 40 mg orally once daily

Third dose reduction: permanent discontinuation.